CompaniesInvestorsPeople
Home
Loading

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

Get in Touch

  • Contact

  • Request a Demo

  • Request Data Updates

  • Add a Company

Research

  • Companies

  • Investors

  • People

aVenture

  • Download App

  • Pricing

Download the aVenture Research beta for iOS and iPadOSDownload aVenture Research on the Mac App Store

Resources

  • Documentation

  • Use Cases

  • CLI

  • MCP

  • Feature Requests

  • Sitemap

Member

Backed by

Ask AI about aVenture

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy · Terms of Service

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading
Home›
Companies›
Basata›
Analysis
Basata

Basata

Basata is an AI company rebuilding the operational layer of US healthcare with specialty-specific AI agents that automate administrative workflows.

Operating headquarters
Tempe, AZ, US🇺🇸
Founded
2024
Loading
Overview
Analysis
Compare
Fundraising
Employees
News
Library
Number of Customers
500,000

Contents

  1. 01Executive Summary
  2. 02Products & Services
  3. 03Market Outlook
  4. 04Competitive Strengths
  1. 01Executive Summary
  2. 02Products & Services
  3. 03Market Outlook
  4. 04Competitive Strengths

Memo

Basata raised a total of 24.5M including a 21M Series A led by Basis Set Ventures with participation from Cowboy Ventures PHX Ventures Zenda Capital and Victoria Treyger. The funding was announced in May 2026.

The company also expanded its partnership with Tri-City Cardiology and hired Brandon Theophilus former NextGen Healthcare GM as SVP of Growth to lead scaling strategy.

Source: prnewswire.com

Product Overview

Basata builds specialty-specific AI agents that automate administrative workflows for healthcare practices. The platform handles referrals, patient intake, scheduling, follow-ups, and EHR updates — replacing fax machines and phone calls with autonomous agents that understand medical specialty workflows.

The system integrates with existing EHR systems and toolsets, allowing practices to accomplish in seconds what previously took hours. Basata's forward-deployed engineering approach tailors AI agents to each medical specialty's unique administrative processes, serving cardiology, urology, gastroenterology, and ophthalmology practices.

Source: finsmes.com

Market Outlook

Basata is addressing the one trillion dollar operational layer of US healthcare which still runs on fax machines and phone calls. The platform replaces manual processes with AI agents.

Practices using Basata report zero backlog at Southwest Cardiovascular and an 18 percent boost in new patient conversions demonstrating the transformative impact of automation.

Source: prnewswire.com

Competitive Advantages

Basata enables practices to process 100% of incoming referrals the same day unlocking 50% more administrative labor capacity. This reduces time-to-first-patient-contact from weeks to minutes.

The platform serves cardiology urology gastroenterology and ophthalmology practices with specialty-specific AI agents that understand the unique workflows of each medical specialty.

Source: basata.ai